Androgen Gel is NOT Appropriate for Pain Treatment
Testosterone gel should not be used to treat pain in adult males. The FDA-approved indication for testosterone gel is strictly for replacement therapy in men with documented androgen deficiency due to primary hypogonadism or hypogonadotropic hypogonadism—not for pain management 1.
Why Testosterone Gel is Not a Pain Treatment
FDA-Approved Indications Are Specific
Testosterone gel is indicated only for conditions with deficiency or absence of endogenous testosterone due to testicular or hypothalamic-pituitary dysfunction 1. Pain is not among the approved indications, and the FDA explicitly states that safety and efficacy in "age-related hypogonadism" have not been established 1.
Clinical Guidelines Do Not Support Use for Pain
The Endocrine Society guidelines (2006,2010) recommend testosterone therapy exclusively for symptomatic men with androgen deficiency who have consistently low testosterone levels to improve sexual function, sense of well-being, muscle mass, and bone density 2, 3. Pain is notably absent from the list of target symptoms. The guidelines explicitly recommend against offering testosterone therapy as a general policy to older men with low testosterone 2.
Research Evidence Shows No Benefit for Pain
The evidence regarding testosterone and pain is contradictory at best:
A 2025 systematic review and meta-analysis found no support for androgens affecting experimental pain sensitivity in adults with or without chronic pain 4. Meta-analyses showed no relationship between testosterone levels and pain ratings.
In opioid-induced androgen deficiency, a 2015 randomized controlled trial showed testosterone improved pressure and mechanical hyperalgesia (objective measures) but did not improve self-reported clinical pain—the outcome that matters most to patients 5.
A 2017 trial in men with opioid-induced androgen deficiency found testosterone did NOT improve pain catastrophizing, a key psychological component of chronic pain 6.
A small 2015 fibromyalgia pilot study (n=12) suggested some benefit for muscle pain, but this was an uncontrolled Phase I/II study with significant methodological limitations 7.
The Critical Distinction: Hypogonadism vs. Pain
If a male patient presents with pain AND has documented hypogonadism (total testosterone <300 ng/dL on two separate morning measurements with consistent symptoms of androgen deficiency), then:
- Treat the hypogonadism according to Endocrine Society guidelines 2, 3
- Treat the pain with evidence-based pain management strategies
- Do not expect testosterone replacement to directly address the pain
The appropriate workup requires:
- Two separate morning total testosterone measurements showing levels <300 ng/dL
- Symptoms of androgen deficiency (decreased libido, erectile dysfunction, decreased energy, reduced muscle mass)
- Exclusion of contraindications: prostate cancer, breast cancer, PSA >3-4 ng/mL, hematocrit >50%, severe heart failure, severe urinary symptoms 2
Common Pitfalls to Avoid
Do not prescribe testosterone gel for pain alone. This represents off-label use without supporting evidence and exposes patients to potential harms including:
- Polycythemia (hematocrit >54%) requiring treatment discontinuation 3
- Prostate complications
- Transfer to women and children through skin contact 1
- Cardiovascular risks in certain populations
Do not assume low testosterone is causing pain. The 2020 American College of Physicians evidence report concluded that in older men with low testosterone without established medical causes of hypogonadism, testosterone therapy provides "little to no benefit" for common symptoms of aging beyond small improvements in sexual function 8.
The Bottom Line
Pain requires appropriate pain management strategies based on its etiology. Testosterone gel is a hormone replacement therapy for documented androgen deficiency, not an analgesic. Using it for pain represents inappropriate prescribing that lacks evidence, violates FDA indications, and potentially harms patients.